Irregular Heartbeat Shown To Increase Risk Of Death As Well As Disability; Particularly Harmful To Women

September 07, 1998

DALLAS, September 8-- Atrial fibrillation -- a condition in which the heart beats irregularly -- significantly increases the risk of dying, particularly for women, report scientists in today's Circulation: Journal of the American Heart Association.

According to the study, men with atrial fibrillation (AF) had a risk of death 1.5 times greater than men without AF. For women, the risk of death was 1.9 times greater in women with AF when compared to women without AF.

Prior research has shown that the condition results in more disability, but in this study researchers looked specifically at death rates and found people with atrial fibrillation had an increased risk of death.

"Women tend to live longer than men," says the study's lead author Emelia J. Benjamin, M.D., associate professor of medicine at Boston University School of Medicine and director of echocardiology for the Framingham Heart Study. "However, in our study, the risk of dying for women with atrial fibrillation at any given age looked similar to men of the same age who had atrial fibrillation."

In the study, the risk for men is heavily influenced by death in the first 30 days after diagnosis, while the increased risk of death for women continues throughout life, says Benjamin. The odds that a woman with AF would die prematurely were actually higher than those for men with the disorder, eliminating the survival advantage that women generally have over men.

AF is caused by a disruption in the rhythm of the atria, the heart's upper two chambers. It causes an irregular heartbeat that results in the heart pumping blood less effectively. About 2 million Americans have AF, according to an editorial in Circulation: Journal of the American Heart Association by J. Thomas Bigger Jr., M.D., professor of medicine and of pharmacology at Columbia University in New York City.

As the Baby Boom generation ages, AF and the sickness and deaths it causes will increase, says Bigger. He also urges greater effort to treat and prevent the disorder.

Because AF often occurs along with other cardiovascular disorders, including heart attacks and stroke, physicians have debated whether it increases a person's risk of death or if it merely reflects the presence of other serious problems.

"We wanted to establish if there was an increased mortality associated with atrial fibrillation," Benjamin explains. "We wanted to answer this question: Are people with atrial fibrillation more likely to die than people without it after adjusting for other risk factors which are known to cause excess death?"

To find the answer, the researchers used data gathered in the Framingham Heart Study. For 50 years, the study, sponsored by the National Heart, Lung, and Blood Institute, has tracked the cardiovascular health of a group of people living in Framingham, Mass.

The scientists examined the medical records of the 5,209 people in the study and found that 621 of them -- 296 men and 325 women -- developed AF between the ages of 55 and 94. Statistical models were used for such risk factors as age, smoking, diabetes, and cardiovascular disorders, including heart attacks, congestive heart failure, and strokes.

People who had AF were more likely to have other cardiovascular risk factors. When the researchers examined this, AF proved an independent risk factor for death.

The researchers also found the risk of dying increased with AF for both sexes in all the age groups studied. For example, men diagnosed with AF between 55 and 64 lived a median of 12.6 years after diagnosis; men of the same age without AF lived 18.1 years. Women in the same age group with the disease had a median survival of 12.1 years compared to 21.3 years for women without it.

"Within the age range we studied, we showed that atrial fibrillation is bad for you," Benjamin says.

The study did not look at the effectiveness of treating AF. However, clinical studies have found some benefit from giving patients the blood-thinning drug warfarin.

In the editorial, Bigger notes a number of therapies for AF are in development or human testing. They include new antiarrhythmic drugs, several new strategies using pacemakers, new surgical and catheter techniques, and implanted atrial defibrillators.

Co-authors of the paper are Philip A. Wolf, M.D.; Ralph B. D'Agostino, Ph.D.; Halit Silbershatz, Ph.D.; William B. Kannel, M.D.; and Daniel Levy, M.D.

Media advisory:

Dr. Benjamin can be reached by phone at (617) 638-8968 or (617) 638-8700 or by e-mail at emelia@fram.nhlbi.nih.gov. (Please do not publish number.)
-end-


American Heart Association

Related Atrial Fibrillation Articles from Brightsurf:

Atrial fibrillation less deadly than it used to be, but still cause for concern: BU study
A first-of-its-kind study by researchers from the Boston University School of Public Health (BUSPH) shows a decline in deaths related to atrial fibrillation (irregular heartbeat) over the last 45 years.

Postoperative atrial fibrillation does not impact on overall survival after esophagectomy
Volume 11, Issue 25 of Oncotarget reported that Administration of landiolol hydrochloride was found to be associated with reduced incidence of atrial fibrillation after esophagectomy for esophageal cancer in our previous randomized controlled trial.

People with atrial fibrillation live longer with exercise
More than 100,000 Norwegians have atrial fibrillation. They should be actively exercising for their health.

Atrial fibrillation among overweight people is not due to fat
In a recently published study, researchers from Aarhus University document that the risk of atrial fibrillation is not linked to the amount of body fat, but instead to large muscle mass, or more precisely, a high fat-free weight

Eating more protein could help ward off atrial fibrillation in women
Women who ate slightly more than the recommended daily amount of protein were significantly less likely to develop atrial fibrillation (AFib), a dangerous heart rhythm disorder that can lead to stroke and heart failure, when compared with those who consumed less protein, according to research being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Zebrafish teach researchers more about atrial fibrillation
Genetic research in zebrafish at the University of Copenhagen has surprised the researchers behind the study.

Personalized medicine for atrial fibrillation
The study, published in Europace, uses signals from implantable devices -- pacemakers and defibrillators -- to analyze electrical signals in the heart during episodes of atrial fibrillation.

Prescribing anticoagulants in the ED for atrial fibrillation increases long-term use by 30%
Patients prescribed anticoagulants after a diagnosis of atrial fibrillation in the emergency department are more likely to continue long-term use of medications to treat the condition, according to research published in CMAJ (Canadian Medical Association Journal).

Anticoagulant benefits for atrial fibrillation decrease with age
The net clinical benefit of anticoagulants for atrial fibrillation (AF) -- one of the most important causes of irregular heartbeats and a leading cause of stroke -- decreases with age, as the risk of death from other factors diminishes their benefit in older patients, according to a study led by researchers at UC San Francisco.

Research improves understanding of mechanism of atrial fibrillation
Mouse model studies show that noncoding DNA regions linked to atrial fibrillation risk can display long-range regulatory functions directed at Pitx2 gene and in this way predispose to the condition.

Read More: Atrial Fibrillation News and Atrial Fibrillation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.